

Definiton

The clinical presentations of CAD include:


- silent ischaemia
- stable angina pectoris
- heart failure
- **unstable angina**
- **myocardial infarction (MI)**
- **sudden death**

Acute coronary syndromes

ACS are usually divided into:


- Unstable angina - only ischemia, lack of necrosis
- STEMI - ST - elevation MI
- NSTEMI - non-ST elevation MI
- Sudden death - due to cardiac arrhythmias

Acute coronary syndromes




Definition

- **ST-elevation ACS**
(STE-ACS):
- typical acute chest pain and persistent (>20 min)
- ST-segment elevation
- generally reflects an acute total coronary occlusion
- most will ultimately develop an ST-elevation MI (STEMI).




ST elevation on the ECG




Definition

- **non-STE-ACS (NSTE-ACS):**
- acute chest pain
- without persistent ST-segment elevation
- persistent or transient ST segment depression or T-wave inversion
- further qualified into non-ST elevation MI (NSTEMI) or unstable angina.




ST depression on the ECG



ACS with persistent ST-segment elevation



Adapted from Michael Davies




Troponin elevated

ACS without persistent ST-segment elevation



Adapted from Michael Davies



Troponins elevated or not


Pathophysiology of ACS

Atherothrombosis


- **Atherosclerosis** - a fixed and barely reversible process of gradual luminal narrowing
(slowly over decades)
- **Thrombosis** - a dynamic and potentially reversible process causing rapid complete or partial occlusion of the coronary artery

Vulnerable plaque

- a **large lipid core**
- a low density of smooth muscle cells
- a high concentration of **inflammatory cells**
- a **thin fibrous cap** covering the lipid core
- **acute thrombosis** induced by a plaque rupture



Vulnerable plaque



Prognosis of STE vs. NSTEMI-ACS

Hospital mortality

- higher in patients with STEMI than among those with NSTEMI-ACS (7 vs. 5%)

6 months mortality


- the mortality rates are very similar in both conditions (12 vs. 13%)

Long-term follow-up

- death rates higher among those with NSTEMI-ACS than with STEMI-ACS

STEMI versus NSTEMI

Hospital vs 1-Year-Mortality



Myocardial infarction

1. Atherosclerotic aetiology (type 1)

2. Non-atherosclerotic aetiology: (type 2-5)

- arteritis
- trauma
- dissection
- congenital anomalies
- cocaine abuse
- complications of cardiac catheterization, CABG

Diagnosis of acute MI

2 from 3 criteria must be fulfilled :

- **Clinical symptoms**
 - Chest pain
- **ECG changes**
 - ST elevation or depression
 - negative T wave
- **Elevated cardiac biomarkers**
 - Troponin I or T
 - CK-MB
 - myoglobin

Diagnosis of ACS

- Clinical presentation
- History of patient
- Physical examination
- Electrocardiogram
- Biochemical markers - troponin
- Non-invasive imaging - Echo
- Imaging of coronary arteries - coronary angiography

Clinical presentation

STE/NSTE-ACS:


- Intense prolonged (20 min) pain at rest - retrosternal pressure or heaviness ('angina') radiating up to the neck, shoulder and jaw and down to the ulnar aspect of the left arm
- May be accompanied by other symptoms such as diaphoresis, nausea, abdominal pain, dyspnoea,...

Unstable angina:

- New onset severe angina (class III of CCS)
- Recent destabilization of previously stable angina with at least CCS III angina characteristics (crescendo angina)
- Post-MI angina.

Clinical presentation

1) Typical chest pain



2) Nausea

3) Sweating

Clinical presentation

Atypical presentations are not uncommon

- epigastric pain
 - recent-onset indigestion
 - stabbing chest pain
 - chest pain with some pleuritic features
 - increasing dyspnoea
- often can be observed in younger (25-40y.), older (75y.), in women, in pts. with diabetes, chronic renal failure, or dementia.

Clinical presentation

- The presence of **tachycardia, hypotension,** **or heart failure** needs rapid diagnosis and management, often indicating a poor prognosis of this patient with ACS
- It is important to identify the clinical circumstances such as **anaemia, infection, inflammation, fever,** and metabolic or endocrine (in particular **thyroid**) disorders (may exacerbate or precipitate ACS)

Physical examination

- Frequently **normal**
- Signs of **heart failure** or haemodynamic instability
- **Dif. dg.:**
 - nonischaemic cardiac disorders: pulmonary embolism, aortic dissection, pericarditis, valvular heart disease)
 - extra-cardiac causes: pulmonary diseases - pneumothorax, pneumonia, pleural effusion)



Physical examination

- Heart failure
 - Tachycardia, tachypnoe
 - Pulmonary rales (pulmonary congestion)
 - RV failure - ↑ jugular congestion, hepatomegaly
- Hypotension ↓ 100/60 mmhg
 - cardiac shock (tachycardia)
 - ↑ vagal nerve activity (bradycardia - inferior IM)
- Bradycardia
 - AV block
 - Inferior IM - non-serious, frequent
 - Anterior IM - serious, rare

Electrocardiogram

- The resting 12-lead ECG is the **first-line diagnostic tool** in the assessment of patients with suspected ACS.
- STE-ACS... ST-elevation
- NSTEMI-ACS...ST-segment shifts and T-wave changes
- A completely **normal ECG does not exclude the possibility of ACS.**


Location of MI



Location of MI


ST elevation only:

- Anteroseptal - V1-V3
- Anterolateral - V1-V6
- Inferior wall - II, III, aVF
- Lateral wall - I, aVL, V4-V6
- Right ventricular - RV4, RV5
- Posterior- R/S ratio >1 in V1 and T wave inversion




Location of MI

Anterior MI




Location of MI

Lateral MI



Location of MI

Inferior MI




Biochemical markers

Markers of **myocardial injury**:

- **cardiac troponins (I and T)**
 - creatinine kinase (CK)
 - CK isoenzyme MB (CK-MB)
 - Myoglobin
-
- **repeated blood sampling** and measurements are required 6–12 h after admission and after any further episodes of severe chest pain

Biochemical markers in ACS



(Modified from Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Committee to Revisit the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction]. American College of Cardiology Web site, 2006. (www.acf.org/clinical/guidelines/stemi/index.pdf). Accessed 9/21/06.)

Biochemical markers

Non-coronary condition with Troponin elevation

- Severe congestive heart failure
- Aortic dissection, valve disease
- Myocarditis
- Hypertrophic CMP, Stress CMP
- Hypertensive crisis
- Acute and chronic renal failure
- Acute neurological disease
- ...

Other biomarkers

- **C-reactive protein** - inflammation
 - long-term prognosis
- **Natriuretic peptides** - heart failure
 - short-term prognosis
- **Serum creatinine** - renal function
 - Short and long-term prognosis

No role for the diagnosis of ACS, but effect on short- or long-term prognosis and dif. Dg.

Non-invasive myocardial imaging

- **Echocardiography**

- to evaluate LV systolic function, aortic stenosis, aortic dissection, pulmonary embolism, or hypertrophic cardiomyopathy
- should be **routinely used in emergency** units for the risk stratification

- **Stress echocardiography, stress scintigraphy** - evidence of ischaemia or myocardial viability (in stabilized patients)

Imaging of the coronary anatomy

- The imaging of the coronary anatomy **is the most important diagnostics method** in evaluation of acute coronary syndrome
- The **gold standard** of patients with ACS is conventional invasive **coronary angiography**

Treatment of MI

- while STEMI is an urgent situation with turbulent symptomatology, NSTEMI may have symptoms much milder and above its immediate prognosis is better
- Pts. should stay on coronary care unit - 2-3 days, than standard cardiology department
- the total length of hospitalization is around 1 week
- even after leaving the CCU patients are able to move around the room and in the following days rehabilitate and before discharge they are able to walk up the stairs
- return to job possible approximately one month after the onset of the symptoms

Treatment of STEMI

- Open the occluded artery **as soon as possible** to restore blood flow for the heart

“Time is muscle“

- Check for complication of myocardial infarction and treat them:
 - arrhythmia
 - heart failure
 - bleeding

Pre-hospital management

- **Betablockers** - tachycardia, hypertension
 - Metoprolol - dose 25-50mg oral or 2 mg i.v.
- **ACE inhibitors** - hypertension
 - Perindopril - dose 5 mg oral
- **Diuretic** - heart failure
 - Furosemide 20 - 40mg i.v.
- **Anti-arrhythmic drugs** -no prophylaxis
 - Mesocain 1% 10 mL i.v.
 - Amiodarone 150 mg i.v. bolus

Hospital and discharge therapy

- **Antiplatelet therapy**

- Acetylsalicylic acid - dose 100 mg p.o.
- Clopidogrel 75mg or ticagrelor 90mg twice a day or prasugrel 10mg

- **Statins** - benefit for all patients with IM


- Atorvastatin 40 - 80mg, rosuvastatin 20 - 40mg

- **ACE inhibitors** - benefit for all patient with IM, more expressed in left ventricular dysfunction

- perindopril - dose 5-10 mg oral

- **Betablockers** - 1 - 3 years after MI, longer for pts. With left ventricular dysfunction, tachyarrhythmia

Case report - 1




57-old female smoker, family history of CAD, pain 6 hours, nausea



Complications of MI

- **Early complications**
 - Heart failure, cardiogenic shock
 - Mechanical complications :
 - rupture of free wall of left ventricle
 - ventricular septal defect
 - acute mitral regurgitation
 - Arrhythmia
 - ventricular (up to 48 h)
 - bradycardia (9-25% of pts)
- **Late complications**
 - pericarditis
 - Aneurysm of left or right ventricle


Tamponade



VSD



VSD



Aneurysm

